Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial（Lancet Oncol 2022, Published OnlineSeptember 12, 2022） まとめ ステージIB-IIIA期の完全切除後アジュバントとしてのぺムブロリズマブは無病生…
